Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Clara Dong
JEF
Clara Dong
Jefferies
Wall Street Analyst
★★☆☆☆
#1816
on 13Foresight · ranked by our own returns
46%
Success Rate
+15.3%
Average Return
6 of 13 calls profitable · +5.1% vs benchmark
📈 Across the calls we could measure, roughly 46% of Clara Dong's ratings turned a profit when each position was held for 1 year — averaging +15.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

21 Buy 2 Hold 0 Sell
Clara's Stock Coverage 13 ratings · 2026-06-19
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
VRDN
Viridian Therapeutics
 Feb 26, 2026 BUY Strong Buy
+103.6% avg upside
32 analysts
$45.00
169.40% Upside
 -45.4%
COGT
Cogent Biosciences
 Feb 18, 2026 BUY Strong Buy
+7.4% avg upside
26 analysts
$48.00
42.50% Upside
 -10.7%
OCUL
Ocular Therapeutix
 Feb 17, 2026 BUY Strong Buy
+159.5% avg upside
21 analysts
$28.00
190.51% Upside
 +37.9%
INCY
Incyte
 Feb 11, 2026 BUY Buy
+1.0% avg upside
47 analysts
$120.00
21.32% Upside
 +0.1%
GLUE
Monte Rosa Therapeutics
 Jan 07, 2026 BUY Strong Buy
+27.3% avg upside
14 analysts
$31.00
68.29% Upside
 -21.3%
IBRX
ImmunityBio
 Dec 12, 2025 BUY Strong Buy
+55.2% avg upside
12 analysts
$9.00
28.80% Upside
 +237.7%
OLMA
Olema Pharmaceuticals
 Dec 10, 2025 BUY Strong Buy
+303.7% avg upside
16 analysts
$43.00
355.59% Upside
 -70.0%
KYMR
Kymera Therapeutics
 Dec 09, 2025 BUY Strong Buy
+9.0% avg upside
36 analysts
$122.00
35.69% Upside
 +3.5%
ONC
BeOne Medicines
 Nov 25, 2025 BUY Strong Buy
+28.6% avg upside
28 analysts
$420.00
59.83% Upside
 -21.6%
CNTA
Centessa Pharmaceuticals
 Nov 13, 2025 BUY Buy
-14.4% avg upside
19 analysts
$30.00
24.72% Downside
 +53.5%
HRTX
Heron Therapeutics
 Nov 04, 2025 BUY Strong Buy
+6439.5% avg upside
21 analysts
$5.00
1190.94% Upside
 -62.3%
ALDX
Aldeyra Therapeutics
 Oct 08, 2025 BUY Strong Buy
+716.1% avg upside
21 analysts
$7.00
282.55% Upside
 -70.1%
MLTX
MoonLake Immunotherapeutics
 Sep 30, 2025 HOLD Strong Buy
+51.6% avg upside
20 analysts
$8.00
58.22% Downside
 +167.6%
🔒 8 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Clara Dong — Frequently Asked Questions
How accurate are Clara Dong's stock ratings?
Based on the calls 13Foresight could measure, about 46% of Clara's ratings were profitable over a one-year hold, with an average return of +15.3% per rating, or +5.1% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Clara ranked on 13Foresight?
Clara Dong is currently ranked #1816 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Clara cover?
Clara most recently has ratings on VRDN, COGT, OCUL, INCY, GLUE, IBRX, OLMA, KYMR, ONC, CNTA, HRTX, ALDX and 1 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.